AA
BCAX

ALPS Advisors’s Bicara Therapeutics BCAX Stock Holding History

ALPS Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Buy
66,182
+14,602
+28% +$326K 0.01% 528
2026
Q1 		$1.03M Buy
51,580
+6,602
+15% +$114K ﹤0.01% 579
2025
Q4 		$757K Buy
44,978
+18,600
+71% +$318K ﹤0.01% 642
2025
Q3 		$417K Sell
26,378
-3,045
-10% -$34.1K ﹤0.01% 900
2025
Q2 		$273K Buy
+29,423
New +$351K ﹤0.01% 955

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ALPS Advisors's BCAX Position: Q2 2026 in Review

ALPS Advisors increased its Bicara Therapeutics (BCAX) stake by 28% in Q2 2026, buying an estimated $326K and bringing the position to 66,182 shares worth $1.96M. The position accounts for 0.01% of the portfolio, ranked #528.

ALPS Advisors first reported a position in BCAX in Q2 2025 and has held it in 5 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • ALPS Advisors held 66,182 shares of Bicara Therapeutics worth $1.96M as of Q2 2026.
  • ALPS Advisors bought 14,602 Bicara Therapeutics shares in Q2 2026, an estimated $326K.
  • Bicara Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #528 holding.
  • ALPS Advisors first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.